Mylan Technologies Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN TECHNOLOGIES
MYLAN TECHNOLOGIES has twelve approved drugs.
Summary for Mylan Technologies
| US Patents: | 0 |
| Tradenames: | 15 |
| Ingredients: | 8 |
| NDAs: | 12 |
| PTAB Cases with Mylan Technologies as petitioner: | See PTAB cases with Mylan Technologies as petitioner |
Drugs and US Patents for Mylan Technologies
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Technologies | ESTRADIOL | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 206685-003 | Aug 15, 2018 | AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Technologies | ESTRADIOL | estradiol | SYSTEM;TRANSDERMAL | 201675-002 | Dec 19, 2014 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Technologies | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 207607-002 | Jun 14, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
